Eloxx Pharmaceuticals financials
$15.42+2.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $6.4M | $0.00 | — | — | — | — | — |
| Gross profit | $0.00 | $6.4M | $0.00 | — | — | — | — | — |
| Gross margin | — | 100.0% | — | — | — | — | — | — |
| Operating income | -$6.4M | -$2.5M | -$17.3M | -$34.4M | -$66.0M | -$33.5M | -$50.6M | -$47.6M |
| Net income | -$6.0M | -$3.1M | -$17.1M | -$36.1M | -$66.7M | -$34.6M | -$50.9M | -$47.2M |
| Net margin | — | −49.4% | — | — | — | — | — | — |
| Diluted EPS | $-0.49 | $-0.84 | $-6.63 | $-16.65 | $-38.15 | $-34.40 | $-53.60 | $-58.00 |
| EBITDA | -$6.4M | -$2.4M | -$17.2M | -$33.7M | -$65.1M | -$28.9M | -$50.0M | -$46.8M |
| Operating cash flow | -$6.3M | -$4.7M | -$14.3M | -$31.8M | -$35.0M | -$28.2M | -$39.4M | -$31.4M |
| Free cash flow | -$6.3M | -$4.7M | -$14.3M | -$31.9M | -$35.1M | — | -$39.4M | -$31.6M |
| Diluted shares | 12.3M | 3.8M | 2.6M | 2.2M | 1.7M | 1.0M | 1.0M | 0.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.8M | $111.0K | $1.1M | $19.2M | $42.3M | $24.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $1.0M | $7.1M | $3.9M | $12.5M | $12.0M | $11.6M |
| Total assets | $5.3M | $3.0M | $1.7M | $21.1M | $45.1M | $26.5M |
| Total liabilities | $17.2M | $27.3M | $24.3M | $31.8M | $22.8M | $16.2M |
| Shareholders' equity | -$11.9M | -$24.3M | -$22.6M | -$10.7M | $22.4M | $10.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology